Genomind continues relationship with the National Association of Psychiatric Health Systems
CHALFONT, PA – March, 11th 2013 – Genomind, a personalized medicine company, is pleased to announce their participation at the National Association of Psychiatric Health Systems Annual Meeting, to be held March 11-13, 2013, in Washington, DC. This will be Genomind’s third year attending and exhibiting at this meeting.
NAPHS is a national organization that advocates for behavioral health and represents provider systems which serve patients with mental and substance abuse disorders. The NAPHS Annual Meeting is a gathering of respected names in the mental health field from both the federal and commercial perspectives, and will include an agenda focused on improvements, new findings, and a positive outlook at the future of the industry.
Genomind is committed to the advancement of personalized medicine for the treatment of psychiatric disorders, and is a strong supporter of psychiatric health care systems. Genomind also understands the challenges of hospitals, institutions, and other facilities as they manage patient health — nearly 50% of patients suffering from depression and other psychiatric disorders fail the first line of therapy and do not achieve remission. Genomind’s Genecept™ Assay, a saliva-based genetic test that identifies genes and biomarkers that may affect a patient’s response to various medications or treatments, can become a helpful tool for health systems, reducing the time in which responsive treatments are administered, improving patient outcomes, and decreasing the costs associated with medication trial-and-error.
The patient’s genetic data provided by the Assay, combined with the clinician and patient consultation which are included with every test, enhances the clinician-patient relationship, streamlines patient management, contributes to cost containment, and enhances an institution’s reputation for bringing the most advanced science to the clinic. These factors improve an institution’s overall reputation as a leader in care deliver and Genomind is looking forward to enhancing the partnership they already have in place today.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at https://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind